Numinus Wellness Inc. (TSX: NUMI | OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that its Toronto clinic, the Neurology Centre of Toronto (NCT) by Numinus, is now offering ketamine-assisted therapy for patients with neurologic conditions.
“Following a thorough evaluation, Numinus found NCT’s existing infrastructure, client base and practitioners to be highly suitable for offering ketamine-assisted therapy. Mental health challenges are commonly associated with neurologic diagnoses and ketamine-assisted therapy is a promising tool that we now have available for our patients. The use of ketamine-assisted therapy within the field of neurology is novel, and we look forward to expanding access for our patients and contributing to the body of knowledge regarding ketamine applications.”
Dr. Evan Lewis (MD), VP, Psychedelic Neurology, Numinus
NCT focuses on conditions including epilepsy, concussion, brain injury and functional neurological disorders, offering a comprehensive range of services that include primary neurologic care and supportive therapies offered by a team of over 20 specialists. The new service will be led by a psychologist and follow Numinus’ existing protocol for ketamine-assisted therapy, already in use in its other locations in Canada and the US, which includes sessions for medical screening, medicine dosing and therapy for integration. The protocol will be modified to ensure it is appropriate for patients with neurologic conditions. A group of existing patients have been reviewed as candidates, with plans to provide treatment to more patients following evaluation of the initial cohort.
In addition to ketamine-assisted therapy, NCT is expanding its capabilities to support applications for other psychedelic-assisted therapies through Health Canada’s Special Access Program (SAP). The SAP is a federal program through which patients with demonstrable need can apply for access to investigational medical treatments that are not yet available to the public, including therapies using psychedelics such as MDMA and psilocybin. A successful SAP application was recently completed by a Montreal Numinus physician to provide psilocybin-assisted therapy for depression.
“We look forward to making psychedelic-assisted therapies more accessible to those in need in Ontario through ketamine-assisted therapy and Special Access Program applications,” said Payton Nyquvest, CEO and Founder, Numinus. “Our patients often face complex challenges, including comorbid neurologic and mental health disorders. By offering these additional services, we can help alleviate their distress and improve their quality of life.”
About Numinus
Numinus Wellness helps people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Numinus model – including psychedelic production, research and clinic care – is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance use. At Numinus, we are leading the integration of psychedelic-assisted therapies into mainstream clinical practice and building the foundation for a healthier society.